Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 12/20 | 0.50 |
| ▸ | KDR | P35968 | 2/20 | 0.45 |
| ▸ | MAPK13 | O15264 | 1/20 | 0.41 |
| ▸ | MAPK12 | P53778 | 1/20 | 0.41 |
| ▸ | MAPK11 | Q15759 | 1/20 | 0.41 |
| ▸ | MAPK14 | Q16539 | 1/20 | 0.41 |
| ▸ | ATG4B | Q9Y4P1 | 1/20 | 0.41 |
| ▸ | PTGES | O14684 | 1/20 | 0.40 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.40 |
| ▸ | FBP1 | P09467 | 1/20 | 0.40 |
| ▸ | LIMK1 | P53667 | 1/20 | 0.40 |
| ▸ | GAA | P10253 | 1/20 | 0.40 |
| ▸ | MAPT | P10636 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6155087 | 0.80 | KMO (0.56) | EGFRKDRMAPK13MAPK12MAPK11 | |
| SCHEMBL3603733 | 0.74 | MEN1 (0.43) | KDRATG4BLIMK1GAAMAPT | |
| SCHEMBL4063056 | 0.72 | TDP1 (0.68) | EGFRMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL30791403 | 0.70 | EGFR (0.65) | EGFRFBP1MAPT | |
| SCHEMBL645368 | 0.70 | EGFR (0.65) | EGFRFBP1MAPT | |
| SCHEMBL219638 | 0.69 | MGAM (0.57) | MAPK14LIMK1GAAMAPT | |
| SCHEMBL1663676 | 0.68 | EGFR (0.54) | EGFRPTGESALOX5FBP1GAA | |
| SCHEMBL1804664 | 0.68 | MEN1 (0.68) | KDRMAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL9788014 | 0.68 | ADORA3 (0.53) | EGFRPTGESALOX5MAPT | |
| SCHEMBL2331528 | 0.67 | ALDH1A1 (0.65) | EGFRPTGES |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050065118-A1 | Organosulfur inhibitors of tyrosine phosphatases | METABASIS THERAPEUTICS, INC. | 2005-03-24 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065118-A1 | Organosulfur inhibitors of tyrosine phosphatases | PTPRS, PTPRJ, PTPRCAP | EGFR 1109/4885KDR 2876/4885MAPK13 2118/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.